You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
SBC: Path Biotech, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions
SBC: ANEUVAS TECHNOLOGIES INC Topic: 104Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus
SBC: Epifocus LLC Topic: 104The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Dodecafluoropentane emulsion (DDFPe), NanO2™ as Cerebroprotectant in Ischemic Stroke
SBC: NUVOX PHARMA, L.L.C. Topic: NINDSABSTRACT / PROJECT SUMMARY Stroke affects more than 795,000 patients per year in the US and kills approximately 40,000. Long-term medical care expense for stroke in the US, costs over $34B per year. Large vessel occlusion (LVO) stroke accounts for almost 40% of ischemic strokes but causes 95% of mortality and 62% of long-term dependence. Mechanical thrombectomy (MT), or a combination of MT and tPA ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Enabling Toxoplasma gondii Kinome Directed Drug Discovery
SBC: LUCEOME BIOTECHNOLOGIES, L.L.C. Topic: NIAIDProject Summary Toxoplasma gondii (T.gondii), the causative agent for toxoplasmosis, invades host cells through ingestion of uncooked infected meat or contaminated water. T.gondii infects 30% of the world’s population and the current cost of the disease in US itself is estimated to be $3B and rising. Current treatment regimen is effective only against acute infection and has severe side effects. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
HazMat Risk Management, Readiness and Training Platform
SBC: INXSOL LLC Topic: NIEHSPROJECT SUMMARY/ABSTRACT HazMat Risk Management, Readiness and Training Platform A unique aspect of hazardous material incidents is that they affect stakeholders in the community with different roles and priorities. Workers in facilities who regularly use or handle hazardous materials, transportation carriers, neighboring communities, first responders, and first receivers (health care workers) are ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
SBC: NEUTHERAPEUTICS, LLC Topic: NIAProject Summary/Abstract Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. Current thinking in the field embraces the complexity of AD pathophysiology, which has enabled a more dive ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Home Monitoring of Metabolic Disorders
SBC: SEQUITUR HEALTH CORP Topic: NICHDPROJECT SUMMARY This proposal is submitted in direct response to NOT-HD-22-009 Notice of Special Interest (NOSI): Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities [IDD] (R43/R44). Persons of all ages with certain metabolic disorders are at-risk for metabolic crises when a certain metabolite accumulates, whi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Islet dosing and loading density in injection molded macroencapsulation devices
SBC: IMMUNOSHIELD THERAPEUTICS INC. Topic: 200PROJECT SUMMARY/ABSTRACT: Clinical islet transplantation is a promising alternative therapy for the treatment of type 1 diabetes, with the potential to reduce or eliminate secondary complications and adverse events. The potent immune response to islets remains the greatest challenge to long-term engraftment and function, which necessitates large numbers of islets and typically multiple pancreatic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Accelerated absorption of insulin via a subcutaneously implanted, vascularized micro-chamber
SBC: PROCYON TECHNOLOGIES LLC Topic: 200Project Summary In Type I diabetic (T1D) patients, insulin is injected into the subcutaneous (SC) tissue, by needle or a pump and SC cannula. A bolus of insulin SC reaches its peak in about one hour or more. This slow absorption is in dramatic contrast to the secretion of insulin into the blood by the normal human pancreas, a process measured in seconds. Consequently, patients with T1D often strug ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health